Lyell Immunopharma Revenue and Competitors
Estimated Revenue & Valuation
- Lyell Immunopharma's estimated annual revenue is currently $10.1M per year.
- Lyell Immunopharma's estimated revenue per employee is $33,800
- Lyell Immunopharma's current valuation is $1.5B. (January 2022)
Employee Data
- Lyell Immunopharma has 300 Employees.
- Lyell Immunopharma grew their employee count by -13% last year.
Lyell Immunopharma's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Head Data Analytics Engineering | Reveal Email/Phone |
2 | Associate Director, Total Rewards | Reveal Email/Phone |
3 | Director, Flow Cytometry | Reveal Email/Phone |
4 | Director | Reveal Email/Phone |
5 | Lead | Reveal Email/Phone |
6 | Associate Director, Head Process and Product Lifecycle Management | Reveal Email/Phone |
7 | Engineer | Reveal Email/Phone |
8 | Associate Director, Compliance and Change - IT | Reveal Email/Phone |
9 | Scientist I | Reveal Email/Phone |
10 | Senior Research Associate | Reveal Email/Phone |
Lyell Immunopharma Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Lyell Immunopharma?
We are entering a new era of medicine, where cancer is treated with cellular therapies: living, smart, targeted drugs. While enormous strides have been made, especially in hematologic cancers, the full promise of these therapies still lies ahead. Cell-based immunotherapies have yet to show substantial benefit in solid tumors, which represent the vast majority of cancers. Our goal is nothing less than to develop curative cell-based immunotherapies for any cancer, with a focus on CAR-Ts and solid tumors.
keywords:N/A
N/A
Total Funding
300
Number of Employees
$10.1M
Revenue (est)
-13%
Employee Growth %
$1.5B
Valuation
N/A
Accelerator
Lyell Immunopharma News
The Goldman Sachs Group cut their target price on shares of Lyell Immunopharma from $31.00 to $21.00 and set a buy rating on the stock in a...
SOUTH SAN FRANCISCO, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (Nasdaq: LYEL), a T-cell reprogramming company...
Form 3 Lyell Immunopharma, Inc. For: Mar 23 Filed by: Albertson Tina M. March 29, 2022 5:08 PM. FORM 3, UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Other Companies in South San Francisco
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $69M | 318 | 19% | $743M |
#2 | $71.8M | 331 | 5% | $306M |
#3 | $127.9M | 379 | 10% | N/A |
#4 | $130.6M | 387 | N/A | N/A |
#5 | $12.8M | 403 | -5% | $59.3M |